Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.

BMC Cancer · 2022 · PMC8722338 · PMID 34980019

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In study 301, which included HER2− ABC patients who had ≤1 prior regimen for ABC, eribulin showed a trend of improved OS compared with capecitabine; however, there was no statistically significant difference (HR, 0.88; 95% CI, 0.77–1.00; P = 0.056, log-rank) [ 4 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.